Rigel Pharmaceuticals
$1.669876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
+$0.01 (0.61%) As of 4:33 PM EDT after-hours
Why Robinhood?
You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!
About RIGL
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Employees
158
Headquarters
South San Francisco, California
Founded
1996
Market Cap
276.55M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.76M
High Today
$1.72
Low Today
$1.62
Open Price
$1.68
Volume
1.62M
52 Week High
$3.64
52 Week Low
$1.60
Collections
Price Paid on Robinhood
39% Lower
Right Now
52 Week Low
$1.96
Average Price Paid
$2.71
52 Week High
$4.12
Analyst Ratings
100%
of 7 ratings
Buy
100%
Hold
0%
Sell
0%
RIGL Earnings
-$0.18
-$0.11
-$0.04
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Nov 5, After Hours